Centurion Shores Up Biotech Outfit With $10M Investment

Law360, New York (October 13, 2011, 6:54 PM EDT) -- Centurion Private Equity LLC is banking on pioneering biotechnology from Amarantus BioSciences Inc., investing $10 million to help the startup develop treatments for Parkinson’s and other diseases, Amarantus announced Thursday.

Centurion is taking a stake in Amarantus as it works to develop therapies based on a protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor. MANF is a disease-modifying protein that corrects apoptosis, or cell death, that characterizes Parkinson’s and ischemic heart disease, the biotech company said in a statement.

“Centurion is pleased to partner with Amarantus to unlock...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.